ADBiotech Valuation

Is A179530 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A179530 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A179530's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A179530's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A179530?

Key metric: As A179530 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A179530. This is calculated by dividing A179530's market cap by their current revenue.
What is A179530's PS Ratio?
PS Ratio	2.5x
Sales	₩9.82b
Market Cap	₩25.00b

A179530 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.2x
Enterprise Value/EBITDA	-9.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A179530's PS Ratio compare to its peers?

The above table shows the PS ratio for A179530 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.4x
A018620 WooGene B&G	0.5x	n/a	₩27.5b
A034940 ChoA Pharmaceutical	0.5x	n/a	₩29.6b
A200780 BCWORLD PHARM	0.5x	n/a	₩37.2b
A080720 Union Korea Pharm	0.2x	n/a	₩15.4b
A179530 ADBiotech	2.5x	n/a	₩25.0b

Price-To-Sales vs Peers: A179530 is expensive based on its Price-To-Sales Ratio (2.5x) compared to the peer average (0.4x).

Price to Sales Ratio vs Industry

How does A179530's PS Ratio compare vs other companies in the KR Pharmaceuticals Industry?

5 Companies	Price / Sales	Estimated Growth	Market Cap
A009290 Kwang Dong Pharmaceutical	0.1x	n/a	US$160.13m
A096760 JW Holdings	0.2x	n/a	US$151.97m
A002620 Jeil Pharma Holdings	0.2x	n/a	US$92.44m
A000230 Ildong Holdings	0.1x	n/a	US$55.95m

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A179530 is expensive based on its Price-To-Sales Ratio (2.5x) compared to the KR Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is A179530's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A179530 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A179530's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

JW Pharmaceutical

₩591.4b

Manufactures and sells medicines and medical supplies in Japan and internationally.

A001060

₩23,650.00

-2.3%

-17.5%

Hugel

₩2.8t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩259,000.00

-5.3%

67.2%

J2KBIO

₩54.3b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,510.00

2.7%

n/a